Versant Ventures related stories
All articles and analysis
Fund briefs recapCisco expands its incubator, Holtzbrinch closes sixth fund, Eniac raises more for mobile deals and other VC fundraising news worldwide
Fund briefs recapA summary of fundraising news worldwide, including Artis, Obvious, Fenox, IQ Capital, Golden and others
A fearless forecast for 2015Despite the perils of forecasting what the future may hold for Canadian private equity and venture capital firms, it is perhaps now more important than ever to do so, writes Richard Rémillard in an exclusive article for peHUB Canada. His advice for those professionals who are now thinking about what 2015 may hold: Be prepared!
Fonds de solidarité FTQ commits $15 mln to new Versant fundThe Fonds de solidarité des travailleurs du Québec FTQ has committed US$15 million to the newly closed /canada/2014/12/10/versant-ventures-closes-new-305-mln-fund-with-help-of-canadian-lps/ fifth healthcare fund of U.S. venture capital firm Versant Ventures. The Fonds said it backed the US$305 million fund because Versant is making an important contribution of capital and investment models to Québec’s life sciences sector. Earlier this year, Versant launched a new incubator /canada/2014/06/24/versant-ventures-brings-inception-sciences-to-montreal/ in Montréal, Inception Sciences Montréal, which specializes in drug discovery and development.
Newly formed Northern Biologics takes $10 mln from Versant VenturesNorthern Biologics, a biologics startup based in Toronto's MaRS Discovery District, has emerged as the premiere spin-out initiative of Canadian biotechnology incubator Blueline Bioscience. Blueline, which was launched /canada/2013/12/10/versant-ventures-sets-up-shop-in-vancouver-invests-10-mln-series-a-in-inception-4/ in late 2013 by U.S. venture capital firm Versant Ventures, formed the company in June in partnership with the University of Toronto and University Health Network's Princess Margaret Cancer Centre. Northern Biologics also received $10 million in a Series A financing from Versant's Fund V, which recently closed /canada/2014/12/10/versant-ventures-closes-new-305-mln-fund-with-help-of-canadian-lps/ at US$305 million. It plans to recruit scientific personnel and advance its portfolio of antibody-based therapeutics for oncology and fibrosis.
Versant Ventures closes new $305 mln fund with help of Canadian LPsU.S. venture capital firm Versant Ventures has closed Versant Venture Capital V LP at US$305 million, surpassing its initial target of US$250 million. The fund will invest across the global healthcare sector and at all stages of company development. Versant, which has an office in Vancouver, has received capital commitments /canada/2014/06/24/teralys-fonds-de-solidarite-ftq-bdc-invest-in-versant-ventures/ for Fund V from a number of Canadian institutional investors, including BDC Capital, Fonds de solidarité FTQ, Northleaf Venture Catalyst Fund and Teralys Capital. This support owed to Versant’s current and planned activity in developing Canada’s life sciences ecosystem.
Versant Ventures closes $305 mln for fifth fundVersant Ventures has raised $305 million for its fifth venture fund, beating its initial $250 million target. The pool will focus on healthcare firms in all stages of development.
- Deerfield leads $42.5 mln round for Audentes
San Francisco-based biotech firm Audentes Therapeutics has secured $42.5 million in Series B financing. Deerfield Management led the round with participation from Sofinnova Ventures, Venrock, OrbiMed, 5AM Ventures and Versant Ventures. As a result of the transaction, Jonathan Leff, a partner at Deerfield, will join Audentes' board of directors.
- IPO Profile: Second Sight Medical Products Inc
Medtech company, focused on eye-related degenerations, had a market cap of more than $537 million at end fo November
- Bayer to invest up to $25 mln in Versant Ventures' newest fund
Versant Ventures' latest fund has added Bayer HealthCare as an LP. Bayer will invest up to $25 million in Versant Venture Capital V. The fund will back the development of new therapies "in areas of high unmet medical need." In addition to investing in the fund, Bayer will join its advisory board.